Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
D 40.91 1.24% 0.50
HALO closed up 1.24 percent on Friday, March 5, 2021, on 1.52 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical HALO trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Spinning Top Other 1.24%
Calm After Storm Range Contraction 1.24%
Lower Bollinger Band Walk Weakness 1.24%
Older End-of-Day Signals for HALO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
1.5x Volume Pace about 9 hours ago
Down 3% about 9 hours ago
60 Minute Opening Range Breakdown about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago
Rose Above Lower Bollinger Band about 10 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Halozyme Therapeutics, Inc. Description

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Solid Tumors Diabetes Antibodies Monoclonal Antibodies Enzymes Insulin Diabetes Mellitus Clinical Trial Product Intrexon Nicu Halozyme Hoffmann La Roche Hyaluronidase

Is HALO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 56.4
52 Week Low 12.71
Average Volume 1,355,424
200-Day Moving Average 34.02
50-Day Moving Average 46.34
20-Day Moving Average 47.52
10-Day Moving Average 45.46
Average True Range 2.73
ADX 25.28
+DI 18.75
-DI 29.72
Chandelier Exit (Long, 3 ATRs ) 48.20
Chandelier Exit (Short, 3 ATRs ) 47.01
Upper Bollinger Band 53.88
Lower Bollinger Band 41.16
Percent B (%b) -0.02
BandWidth 26.78
MACD Line -1.28
MACD Signal Line -0.16
MACD Histogram -1.1174
Fundamentals Value
Market Cap 5.53 Billion
Num Shares 135 Million
EPS 0.15
Price-to-Earnings (P/E) Ratio 265.65
Price-to-Sales 28.54
Price-to-Book 55.46
PEG Ratio -2.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.24
Resistance 3 (R3) 43.91 42.47 43.69
Resistance 2 (R2) 42.47 41.62 42.64 43.50
Resistance 1 (R1) 41.69 41.10 42.08 42.02 43.31
Pivot Point 40.25 40.25 40.45 40.42 40.25
Support 1 (S1) 39.47 39.40 39.86 39.80 38.51
Support 2 (S2) 38.03 38.88 38.20 38.32
Support 3 (S3) 37.25 38.03 38.14
Support 4 (S4) 37.58